U.S. markets close in 8 minutes

Cybin Inc. (CYBN.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
0.6700-0.0100 (-1.47%)
As of 03:39PM EDT. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6800
Bid0.6400 x 0
Ask0.6700 x 0
Day's Range0.6500 - 0.6900
52 Week Range0.5000 - 3.0000
Avg. Volume149,615
Market Cap124.099M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3790
Earnings DateFeb 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CYBN.NE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds

      TORONTO, September 27, 2022--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset") to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules from Mindset (the "Agreement").

    • GlobeNewswire

      Mindset Pharma Provides Strategic Intellectual Property License to Cybin

      Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business StrategyTORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced an exclusive licensing agreement for Cybin Inc. (N

    • Market Exclusive

      Weekly Roundup on the Cannabis Sector & Psychedelic Sector

      Key Takeaways; Cannabis Sector High Tide’s third-quarter revenue rose 18% to C$95.4 million; in addition, the company closed a $19 million non-dilutive credit arrangement. Key Takeaways; Psychedelic Sector Cybin announced key research and development milestones, beating anticipated timeframe. Awakn reported strong Q2 earnings. The company also announced participation in a global investment conference. This week, […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared fir